The development of innovative
homegrown
Japanese pharmaceuticals
and medical technologies
To drive the development and clinical application of innovative by
leveraging RIKEN’s rich life science research infrastructure
News & Topics
-
-
We held the RIKEN exhibition booth and RIKEN seminar at BioJapan 2024 to introduce research strategies and cutting-edge research platforms in the field of drug discovery at the RIKEN.(Japanese only)
-
ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy
-
Tumor epitope spreading by a novel multivalent therapeutic cellular vaccine targeting cancer antigens to invariant NKT-triggered dendritic cells in situ
-
NKT-Licensed In Vivo Dendritic Cell−Based Immunotherapy as Cellular Immunodrugs for Cancer Treatment
-
Safety and stable survival of stem-cell-derived retinal organoid for 2 years in patients with retinitis pigmentosa
-
"Self-organization, quality control, and preclinical studies of human iPSC-derived retinal sheets for tissue-transplantation therapy"
-
Improved retinal transplant technique almost ready for clinical trials
-
RIKEN Research Cluster for Innovation Drug Discovery and Medical Technology Platforms has arranged a new setup（Program Director OKAZAKI Hiroshi）
-
Completion of the first patient treatment for cancer immunotherapy with iPS-NKT cells (Japanese only)
-
Report was published "Establishment of a heart-on-a-chip microdevice based on human iPS cells for the evaluation of human heart tissue function"
-
"Safety Study of allogenic hiPSC-retinas in Retinitis Pigmentosa (hiRERP)"---the surgery was conducted on the first patient at Kobe eye center hospital." (Japanese only)
-
One of the Drug Discovery Chemistry Platform Unit's paper was featured in the Journal of Medicinal Chemistry Virtual Issue which features 15 articles published during 2017-2019 showcasing outstanding medicinal chemistry research from Japan. Title of paper: Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer
-
RIKEN and Lynk Pharmaceuticals enter into exclusive licensing agreement (Japanese only)
-
The University of Tokyo, RIKEN, Nichi-Iko and Daiichi Sankyo Reach Basic Agreement on Collaborative R&D on Nafamostat Inhalation Formulation for Treatment of Novel Corona Virus Infection (COVID-19) (Japanese only)
-
RIKEN DMP launches special project to combat COVID-19
-
Launch of preclinical tests in hair follicle regenerative medicine (Japanese only)
-
Start of investigator initiated clinical trials of cancer treatment by NKT cells (Japanese only)
-
Establishment of immunodeficient retinal degeneration model mice and functional maturation of human ESC-derived retinal sheets after transplantation (Japanese only)
About Us
The role of the Program for Drug Discovery and Medical Technology Platforms is to connect the latest research outcomes of RIKEN research centers to drug discovery and medical technology platforms.
The Program for Drug
Discovery and Medical
Technology Platforms
To support the research and development domains in implementing drug discovery and medical technology, we have established the cutting-edge research technology platform units.
For Partnering
and Aliance
Strategic Alliance Office
The Strategic Alliance Office handles alliances for collaboration with companies, universities, and external research institutes. It is also involved in licensing intellectual property rights to companies in collaboration with RIKEN Innovation.
Translational Research
Office
Mission of Translational Research Office (TRO), the competent team which consists of number of experts of translational research (TR) from industry, academic TR institutes, regulatory organizations, is to support projects establishing clinical development plan.